Skip to main content

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

In the last 90 days, Lipocine Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Lipocine Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of LPCN: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders4649+3
Shares10.8M10.5M−252.9K (−2.3%)
Value$4.85M$4.16M−$693.8K (−14.3%)

New holders (7)

Institutions that held Lipocine Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to LPCN in Q4 2022
InstitutionSharesValue% of portfolio
Bailard, Inc.82,957$31.9K0.00%
Wealthspan Partners, LLC73,950$29.4K0.03%
Two Sigma Securities, LLC16,796$6.68K0.00%
Belvedere Trading LLC4,200$1.67K0.00%
The PNC Financial Services Group, Inc.200$800.00%
NewSquare Capital LLC200$770.00%
Northwestern Mutual Wealth Management Co51$200.00%

Sold out (4)

Institutions that held Lipocine Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of LPCN in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Virtu Financial LLC93,411$42.0K
Mariner, LLC13,675$6.00K
Royal Bank of Canada210$0
Walleye Trading LLC101$0